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Studies on burden of disease and cost of illness 
investigate life loss and economic loss caused by a disease.
1 
They determine the degree of economic loss following a 
disease, to establish governmental policies and to identify 
research topics in a new area.
Comparison the studies among the cost of illness, 
burden of disease, and economic evaluation clarifies their 
characteristics. They use similar terms and methodologies. 
Studies of cost of illness should be differentiated from those 
of burden of disease. While burden of disease is presented 
with disability adjusted life year (DALY) and quality 
adjusted life year (QALY), cost of illness is expressed with 
financial terms. In short, studies on cost of illness measure 
the degree of diseases or risk factors in terms of economic 
burden.
2-5 They show the problems with a currency unit, 
provide a basis for plans and policies for its prevention and 
control, justify intervention programs, and promote the 
allocation of resources and research funds in its area. 
Economic evaluation is the extension of cost of illness. It 
contains both parts of costs and outcomes. However, cost of 
illness and burden of disease only focus on the costs. 
To conduct studies on cost of disease; 1) The definition of 
the disease should be clear and its complications also should 
be included. It is important because the scope of diseases 
influence on the costs incurred. 2) Epidemiological charac-
teristics of the diseases should be exact and updated. The 
more prevalent diseases may cause the more burden on the 
society. 3) Social point of view is recommended usually and 
4) The data for the use of resources and their unit cost should 
be collected and calculated to evaluate the use of resources 
monetarily. Because studies on cost of disease aim to 
estimate its burden, the data for cost should be accurate.
Some published articles could be useful for the cost of 
liver diseases. Many epidemiological results may be use to 
estimate the prevalence of acute hepatitis, chronic hepatitis 
and liver cancer.
6-12 In a study estimated socioeconomic 
costs of five death causes as diseases, in which included 
liver disease, the cost of cancer recorded the highest cost 
burden 7735.8 billion won and liver disease followed and 
recorded 2620.1 billion won.
13 A cost-effectiveness study of 
antiviral therapy for chronic hepatitis B patients could be 
nice source for cost of liver disease, that included the costs 
of chronic hepatitis, hepatic cirrhosis and liver cancer.
14 
However, none of them was used in the study for the cost of 
liver diseases.
15
In a study on cost of diseases, assuming the prevalence of 
an illness is an important starting point. Determining the 
prevalence before estimating its costs following treatments 
for it is also critical from medical and epidemiological 
aspects. The study of Lee et al
15 used national health 
insurance data to estimate cost of liver. It is inevitable to use 
available existing data for estimation prevalence and incidence 
of diseases. However, it may cause some problems to use the 
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reliability of these data are critical in the cost of illness 
studies.
16 It is more appropriate to calculate costs based on 
cases episode rather than cases claimed. 
It has been already known that health insurance statistics 
has many limitations in studies on burden of disease or 
economic evaluation.
5 To cope with them, studies conducted 
in the U.S. utilized costs-to-charge ratio by using charges 
which hospitals imposed on patients, and those in England 
and the Netherlands used standard unit costs data.
17,18 Lee et 
al
15 also pointed out these problems in calculating costs. 
‘Medical care expenses’ determined by Health Insurance 
Review and Assessment Service (HIRA) are not actual 
medical costs but the price of health care services determined 
by Government. 
Studies estimating costs of chronic diseases also have 
tried to overcome these problems. By considering that the 
rate of uninsured out-of-pocket payments in 2008 was 
15.2%, direct medical costs were calculated by applying the 
rate for uninsured medical service. Health utilization 
patterns of acute and chronic hepatitis, hepatic cirrhosis and 
liver cancer have great variances, and each uninsured 
out-of-pocket payments may be different. It should be 
considered the different pattern of utilization to estimate the 
uninsured out-of-pocket payments. 
To estimate direct non-medical costs like time costs and 
traffic costs, previous data are used. These data can be 
important sources to presume costs in economic evaluation. 
Time valuation or national averages which are hard to be 
determined in individual studies can increase the comparability 
with other studies. This study estimating the cost of liver 
disease assumes the average round-trip traffic cost to be 
1475 won in 2008 based on the results of 2008 Korea Health 
Panel Survey. However, it is necessary to verify whether 
estimating the cost with the average visit days of outpatients 
is well-grounded.
For disease such as liver cirrhosis provoking hospitalization, 
long-term care and disability in daily life, it is especially 
important to consider informal care. Costs of informal care 
also should be included. The period of informal care is 
assumed to be same with the length of hospital stay in the 
study of Lee et al,
15 and the mean length of hospital stay by 
disease used the National Health Insurance Statistics data. In 
the view of patients, the need for actual informal care may be 
greater before and after the hospitalization rather than the 
period of in-hospital care. In addition, to estimate the 
productivity loss for liver disease, it is used data for 
hospitalization days and visit days from the National Health 
Insurance Statistical Yearbook. It may be ease to underestimate 
the productivity loss. To evaluation time value such as 
informal care, most studies conducted with a conventional 
human capital method, but the method has a high possibility 
of overestimating the costs of decreased productivity 
following absenteeism, disability and premature death. 
Friction cost methods suggested to overcome it, has been 
applied currently more and more in Europe. When a person 
quits his or her job due to disability or death, his or her 
position is generally supplemented through promotion or 
employment. Therefore, friction cost method calculates 
productivity loss of the total society with the time from a 
point of stopping work to ‘supplementation’ rather than the 
time to ‘retirement’ in the conventional human capital 
method.
19 The lost earnings following liver disease related 
premature death accounts for the highest portion or 73.9- 
86.1% of the total socioeconomic cost. While the weight of 
direct medical cost can be low because of relatively a low 
insurance conversion factor, the cost calculated with human 
capital method shows a high weight.
Studies on cost of disease aim to support decision-making. 
So, they demand methodological validity and soundness. In 
particular, rational data supporting for decision-making on 
national health policies will facilitate evidence based health 
policies. However, most studies on cost of liver disease use 
the same previous methodologies even there were other 
epidemiologic researches results and other methodological 
recommendations, so efforts to improve methodology are 
needed in the future. There is still a gap between political 
demand for decision-making and the level of study to 
provide information for it. But, this problem should be 
recognized very importantly as a good starting point. Systematic 
improvement and supports for studies on cost of illness are 
necessary.
20 
Although a study on cost of liver disease in 2001 insisted 
that its cost was 2620.1 billion won, that of Lee et al
15 reports 
its socioeconomic loss was maximally 8104.3 billion won in 
2006 to show a significant difference between both studies. 
Because the difference is too large even after considering the 
difference in methodology and price rises, its causes need to 
be determined. 
Liver disease is not completely cured, continuous 
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Therefore, comparing change in the proportion of cost 
components as well as the gross costs of illness should be 
considered. It should be prepared to increase access to health 
insurance benefits for managing chronic conditions and 
preventing complications for liver disease patients in the 
future. The change in the proportion of cost of liver diseases 
can be used for the communication tool for expanding health 
care benefits for chronic care. 
Not only decision-makers but also decision-making 
processes are critical for sound in policy decision. Rational 
and open decision-making process will raise the demand for 
evidences and information. In other words, the situational 
context leads to the rational content. From this aspect, it 
should be more open and clear process for health policy. 
Study on cost of illness must be the essential example to be 
utilized for communication among an academic society, 
Ministry of Health, patient associations and the public 
opinion leaders. It has larger political importance compared 
to other studies because it presents the result as costs, which 
is a universal and popular form.
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